🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Frederick H. Wilson

Yale Cancer Center

ORCID: 0000-0002-5019-0186

Also affiliated with Yale University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial”.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30111-x
N/A
6.6DataRank · unranked
541 citations

Kurt A. Schalper, Scott Gettinger, Amit Mahajan, Roy S. Herbst, Anne C. Chiang +19 more

RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4291
N/A
0.920DataRank · unranked
19 citations

Dejian Zhao, Heather Lazowski, Man Li, Yuping Qian, Laura Abriola +8 more

Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9121
N/A
0.104DataRank · unranked
1 citations

Frederick H. Wilson, Sarah B. Goldberg, Anne C. Chiang, Brian S. Henick, Elin Rowen +10 more

A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition

npj Precision Oncology(2024)10.1038/s41698-023-00490-w
N/A
0DataRank · unranked
4 citations

Zaritza O. Petrova, Lisa Hunihan, Kumar Dilip Ashtekar, Zenta Walther, Frederick H. Wilson +1 more